Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

• Published in: Curēus (Palo Alto, CA) Vol. 16; no. 6; p. e63362
• Main Authors: Akdag, Goncagul, Dogan, Akif, Yildirim, Sedat, Kinikoglu, Oguzcan, Mokresh, Muhammed Edib, Alomari, Omar, Turkoglu, Ezgi, Isik, Deniz, Sürmeli, Heves, Basoglu, Tugba, Sever, Ozlem N, Odabas, Hatice, Yildirim, Mahmut E, Turan, Nedim
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 28.06.2024; Cureus
• Subjects: Breast cancer; Cancer therapies; Creatinine; Cyclin-dependent kinases; Epidermal growth factor; Estrogens; Ethics; Internal Medicine; Kinases; Medical prognosis; Metastasis; Monoclonal antibodies; Oncology; Patients; Radiation Oncology; Tumors; metastatic hormone positive breast cancer; rank and rankl; denosumab and cancer; cdk4/6 inhibitor; breast cancer outcomes
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.63362

Breast cancer (BC) remains a significant health concern, particularly in advanced stages where the prognosis is poor. The combination of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has improved outcomes for advanced BC (aBC) patients. However, resistance to CDK4/6i remains a challenge, with no validated biomarkers to predict response. The receptor activator of the nuclear factor-kB (RANK) pathway has emerged as a key player in aBC, particularly in luminal BC. RANK overexpression has been associated with aggressive phenotypes and resistance to therapy. In view of these findings, we proceeded to investigate the potential involvement of the RANK pathway in luminal BC resistance to CDK4/6i. The objective was to evaluate the effectiveness of denosumab in increasing overall survival (OS) and progression-free survival (PFS). In this retrospective analysis, 158 BC patients with bone metastases were included. Patients with human epidermal growth factor receptor-2 (HER2)-negative and hormone receptor-positive BC who received palbociclib or ribociclib in addition to antiresorptive medication were included. Patients received either denosumab or zoledronic acid (ZA) therapy. The primary endpoint was OS, with PFS as a secondary endpoint. Although the PFS and OS of denosumab were better than ZA in this study, it did not show a significant difference between the two drugs. Meanwhile, mOS was not achievable in patients in the denosumab group, while it was 34.1 months in patients in the ZA group. The hazard ratio (HR) showed a significant improvement for the denosumab group in patients under 60 of age (HR: 0.33, p<0.01), patients with a score of 1 HER2 overexpression (HR: 0.09, p=0.01), and patients with resistant endocrine (HR: 0.42, p=0.02) compared to ZA. This study highlights the potential clinical relevance of the RANK pathway in BC treatment, and our findings suggest that denosumab may offer significant benefits in terms of PFS and OS for certain subgroups, particularly those with HER2 scores of 1, patients under 60, and those with endocrine-resistant BC. In conclusion, considering that RANK pathway status may be a predictive biomarker for CDK4/6i treatment and may cause treatment resistance, our results demonstrate the clinical relevance of the combination of CDK4/6i + ET with RANKL inhibition.